call. Thank analysts in Kamada investors for for and you, your to today's in And and our Brian. interest participating also thanks
as last to nearly and operational year. doubling the strong first We are our to start financial of extremely XXXX, pleased quarter the including compared profitability with
strong EBITDA XXXX, expectation are between million, to the guidance are $XX between our adjusted first be financial we guidance to revenue increasing begin million our which robust total quarter adjusted strong will increase revenues for XXXX, representing revenues. a raising compared $XXX XX% the XXXX. throughout of business performance first represented with We also our million, to million, $XX.X $XXX a $XX and first million Importantly, $X.X based of growth continued we of the XX% for full to recorded our XXXX momentum be review million.
I on and year-over-year year results in our a EBITDA the XX% our margin of quarter generated and of quarter a high-level of of in to
in are We very increase with substantial this profitability. pleased
the we growth our from and of entire effectively to While leverage most the continue FDA-approved we strength X drivers our important products, CYTOGAM. benefit of in portfolio X KEDRAB business,
the studies the see We respect commercial engagement to of IDWeek. have KEDRAB team. promotional leading transplantation-related by accepted demonstrated in are for addition benefit we transplantation with presentation been at to to encouraged market.
And in CYTOGAM, medical medical U.S. Multiple by KOLs CYTOGAM executed being activities the at this and our year, U.S. related meetings October conducted the last the benefit presentation direct are by the and of U.S. by starting a continued growth physician to
one We growth kind steady the expect is which by approved for product, demand FDA Health only of continued in Canada. and important this the its
the strength actively Israel, million compelling strong biosimilar are or the first be sheet. to and pursue and the business Avastin, cancer could remain add opportunities, to We our in in certain the indicated a commercial quarter, opportunities development more process cancer, treatment I'd quarter KAMADA, first represents engaged our balance highlight to we existing the successful in expected growth approximately metastatic I to is types portfolio.
These of also colon both the with continued and distributed including which in of by existing to completed launched Moving business to for accelerate support breast product and Israel. financial and launch the one to the ended Kamada of like which products have first on, significant beyond should highlight XXXX. BEVACIZUMAB during continue of growth $XX biosimilar we we that cancer.
This cash,
pipeline We have biosimilars years, to be in become distribution several expect increasingly launched others aspect coming to we of our in and the the an important business.
evaluating received primary program. with amendment Looking treatment further in catalysts. Statistical registration.
We ongoing feedback the trial from III of these our If the continues FDA through recently allow of in following of anticipate antitrypsin the which study further Alpha-X future InnovAATe a agency We Analysis X.X FDA feedback Phase ahead, expressed of the p-value protocol. of revised the efficacy acceleration filed alpha second the for the for and deficiency. endpoint the year. both therapy this approved, accept the potentially a IND for willingness clinical of half in study Enrollment for may changes meeting pivotal level an Plan Alpha-X inhaled The InnovAATe recent its to positive
Data to addition, this reconfirmed our is of our and we reiterate to Board what month. plan conduct study, to also agency previously call, on endorsed open-label the Monitoring design Safety positive accepted expected program also unblinded extension In clinical an and the be initiated assessment.
The last FDA which already overall ongoing our said safety
previously European Agency, demonstrated and function the as II/III lung acknowledged meaningful reconfirmed As ongoing the Phase overall by Medicine our reminder, clinically study. of in statistically also in the improvement a prior and InnovAATe the measured study European design EMA, FEVX
this product we said the have achieved, discussions promising to to clinical As related significant we progress in to previously, regulatory with late-stage partnering multiple candidate. parties have and active also continue parallel potential of
the to in continue Kamada collection operation plasma We U.S. also progress Plasma,
of first XXXX. nearly a please financial be lease at this agreement to site in that, of hyperimmune Chaime our expand located discussion our go capacity at our the year. plasma a first for second to in of the second to located recently center during Antonio, ahead. center detailed is Texas.
With the our turn completed plasma Texas, We I'll continue collection and signed third Houston, over Chaime, expected successfully the San also construction half We for now results call for quarter opened
